Creative Dance-Supported CO-OP Approach in Older Adults With Mild Cognitive Impairment (NCT06644690) | Clinical Trial Compass
CompletedNot Applicable
Creative Dance-Supported CO-OP Approach in Older Adults With Mild Cognitive Impairment
Turkey (Türkiye)26 participantsStarted 2024-11-15
Plain-language summary
The goal of this clinical trial is to evaluate if the CO-OP (Cognitive Orientation to daily Occupational Performance) approach, supported by creative dance, can improve cognitive functions in older adults with mild cognitive impairment (MCI). The study focuses on the effects of this intervention on executive functions, attention, memory, and dual-task performance.
The main questions this study aims to answer are:
Does the CO-OP approach with creative dance improve executive functions, attention, and memory more than CO-OP alone? How effective is this intervention in enhancing dual-task performance compared to the standard CO-OP approach?
Participants will:
Engage in either the CO-OP intervention alone or the CO-OP approach combined with creative dance for 8 weeks.
Complete cognitive tasks, participate in creative dance activities, and perform daily tasks during the sessions.
Who can participate
Age range
65 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age between 65 and 85 years old
* Diagnosis of mild cognitive impairment (MCI) according to DSM-5 criteria
* Ability to participate in physical activities, including creative dance movements
* Willingness to attend all study sessions and follow-up assessments
* Able to give informed consent
Exclusion Criteria:
* Diagnosis of a major neurocognitive disorder (e.g., Alzheimer's disease)
* Presence of severe physical impairments that prevent participation in physical activity
* Current use of medications that significantly affect cognitive function
* Participation in another clinical trial within the past 3 months
* History of significant psychiatric disorders (e.g., major depression, schizophrenia)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in Executive Function as Measured by the Trail Making Test Part B
Timeframe: Baseline, immediately after the 8-week intervention, and at 3 and 6 months post-intervention